Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has successfully completed the 12-week double-blind, efficacy and safety parent study (P00692).~* If female, has a negative pregnancy test prior to study entry and, if of childbearing potential, agrees to practice an effective barrier method of birth control for the duration of the study and for 30 days after the last statin dose.~* If postmenopausal female receiving hormone therapy, a stable estrogen (ERT), estrogen/progestin (HRT) or raloxifene regimen must be maintained during the study period.~* Is willing to continue to follow their prescribed National Cholesterol Education Program (NCEP) Step 1 diet for the duration of the study.~Exclusion Criteria:~* Has discontinued from the parent study (P00692) prior to study completion.~* Is in a situation, or has any condition which, in the opinion of the investigator may interfere with optimal participation.~* Is a pregnant or lactating female.~* Is human immunodeficiency virus (HIV) positive.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 86 Years
- Healthy Volunteers: t

Study Arms:
- Placebo + Atorvastatin (Type: PLACEBO_COMPARATOR): Participants who received placebo in the parent study (P00692) receive placebo (blinded) + atorvastatin (10 mg/day; open-label) in this study.
- Ezetimibe + Atorvastatin (Type: EXPERIMENTAL): Participants who received ezetimibe + atorvastatin, or atorvastatin alone, in the parent study (P00692) receive ezetimibe (blinded) + atorvastatin (10 mg/day; open-label) in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).